The DOI matches its Crossref record; 184 of the 184 references it cites were found in a registry or an index.
Psychosocial interventions for cannabis use disorder
Open accessAbstract
BACKGROUND: Cannabis use disorder is the most commonly reported illegal substance use disorder in the general population; although demand for assistance from health services is increasing internationally, only a minority of those with the disorder seek professional assistance. Treatment studies have been published, but pressure to establish public policy requires an updated systematic review of cannabis-specific treatments for adults. OBJECTIVES: To evaluate the efficacy of psychosocial interventions for cannabis use disorder (compared with inactive control and/or alternative treatment) delivered to adults in an out-patient or community setting. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 6), MEDLINE, EMBASE, PsycINFO, the Cumulaive Index to Nursing and Allied Health Literature (CINAHL) and reference lists of articles. Searched literature included all articles published before July 2015. SELECTION CRITERIA: All randomised controlled studies examining a psychosocial intervention for cannabis use disorder (without pharmacological intervention) in comparison with a minimal or inactive treatment control or alternative combinations of psychosocial interventions. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures as expected by The Cochrane Collaboration. MAIN RESULTS: We included 23 randomised controlled trials involving 4045 participants. A total of 15 studies took place in the United States, two in Australia, two in Germany and one each in Switzerland, Canada, Brazil and Ireland. Investigators delivered treatments over approximately seven sessions (range, one to 14) for approximately 12 weeks (range, one to 56).Overall, risk of bias across studies was moderate, that is, no trial was at high risk of selection bias, attrition bias or reporting bias. Further, trials included a large total number of participants, and each trial ensured the fidelity of treatments provided. In contrast, because of the nature of the interventions provided, participant blinding was not possible, and reports of researcher blinding often were unclear or were not provided. Half of the reviewed studies included collateral verification or urinalysis to confirm self report data, leading to concern about performance and detection bias. Finally, concerns of other bias were based on relatively consistent lack of assessment of non-cannabis substance use or use of additional treatments before or during the trial period.A subset of studies provided sufficient detail for comparison of effects of any intervention versus inactive control on primary outcomes of interest at early follow-up (median, four months). Results showed moderate-quality evidence that approximately seven out of 10 intervention participants completed treatment as intended (effect size (ES) 0.71, 95% confidence interval (CI) 0.63 to 0.78, 11 studies, 1424 participants), and that those receiving psychosocial intervention used cannabis on fewer days compared with those given inactive control (mean difference (MD) 5.67, 95% CI 3.08 to 8.26, six studies, 1144 participants). In addition, low-quality evidence revealed that those receiving intervention were more likely to report point-prevalence abstinence (risk ratio (RR) 2.55, 95% CI 1.34 to 4.83, six studies, 1166 participants) and reported fewer symptoms of dependence (standardised mean difference (SMD) 4.15, 95% CI 1.67 to 6.63, four studies, 889 participants) and cannabis-related problems compared with those given inactive control (SMD 3.34, 95% CI 1.26 to 5.42, six studies, 2202 participants). Finally, very low-quality evidence indicated that those receiving intervention reported using fewer joints per day compared with those given inactive control (SMD 3.55, 95% CI 2.51 to 4.59, eight studies, 1600 participants). Notably, subgroup analyses found that interventions of more than four sessions delivered over longer than one month (high intensity) produced consistently improved outcomes (particularly in terms of cannabis use frequency and severity of dependence) in the short term as compared with low-intensity interventions.The most consistent evidence supports the use of cognitive-behavioural therapy (CBT), motivational enhancement therapy (MET) and particularly their combination for assisting with reduction of cannabis use frequency at early follow-up (MET: MD 4.45, 95% CI 1.90 to 7.00, four studies, 612 participants; CBT: MD 10.94, 95% CI 7.44 to 14.44, one study, 134 participants; MET + CBT: MD 7.38, 95% CI 3.18 to 11.57, three studies, 398 participants) and severity of dependence (MET: SMD 4.07, 95% CI 1.97 to 6.17, two studies, 316 participants; MET + CBT: SMD 7.89, 95% CI 0.93 to 14.85, three studies, 573 participants), although no particular intervention was consistently effective at nine-month follow-up or later. In addition, data from five out of six studies supported the utility of adding voucher-based incentives for cannabis-negative urines to
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Psychosocial treatments such as motivational enhancement therapy, cognitive behavioral therapy, and contingency management produce greater reductions in cannabis use than control treatments [60].”
From Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits (2025) · cites this paper as [60]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There is strong support in the literature and clinical practice for psychosocial interventions for the management of CUD 29, 30.”
From Psychosocial and pharmacological interventions for the treatment of cannabis use disorder (2018) · cites this paper as [30]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“An analysis of the evidence shows that the current best psychosocial intervention to reduce cannabis use is the combination of motivational enhancement therapy and cognitive-behavioral therapy, preferably accompanied by a contingency management approach.”
From Psychosocial and pharmacological interventions for the treatment of cannabis use disorder (2018) · cites this paper as [30]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The criteria for problematic methamphetamine use (PMU) is less well defined; in the literature, it has been defined according to thresholds of use (e.g., daily, monthly), consequences of use (e.g., substance use-related emergency department visit), or measures taken to provide treatment (e.g., in-treatment or treatment seeking) [20, 21].”
From Psychosocial and pharmacologic interventions for problematic methamphetamine use: Findings from a scoping review of the literature (2023) · cites this paper as [20]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings
Denis, C., Lavie, E., Fatseas, M., & Auriacombe, M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005336.pub2 · Cited by 108
RetractedDiagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
Selective Cortical Undercutting As a Means of Modifying and Studying Frontal Lobe Function in Man
Scoville, W. B. (1949) · Journal of neurosurgery · doi:10.3171/jns.1949.6.1.0065 · Cited by 7,374
Cochrane Handbook for Systematic Reviews of Interventions
Tarsilla, M. (2010) · Journal of MultiDisciplinary Evaluation · doi:10.56645/jmde.v6i14.284 · Cited by 5,232
An Improved Diagnostic Evaluation Instrument for Substance Abuse Patients
McLellan, A. T., Luborsky, L. B., WOODY, G. E., & Brien, C. P. O. (1980) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198001000-00006 · Cited by 3,163
A Meta-Analytic Review of Psychosocial Interventions for Substance Use Disorders
Dutra, L., Stathopoulou, G., Basden, S. L., Leyro, T. M., Powers, M. B., & Otto, M. W. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111851 · Cited by 1,287
Comparison of extended versus brief treatments for marijuana use.
Stephens, R. S., Roffman, R. A., & Curtin, L. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.68.5.898 · Cited by 711
Cognitive therapy of substance abuse
FRANCES, R. J. (1994) · General Hospital Psychiatry · doi:10.1016/0163-8343(94)90121-x · Cited by 580
The co‐occurring use and misuse of cannabis and tobacco: a review
Arpana Agrawal, A., Budney, A. J., & Lynskey, M. T. (2012) · Addiction · doi:10.1111/j.1360-0443.2012.03837.x · Cited by 534
Flagged first, then by citations
Research works printed but not linked: 22
- Bonsack, 2008, Practice of a motivational intervention for cannabis users with psychosis, Schweizer Archiv fur Neurologie und Psychiatrie, 159, 378
- Peters, 2011, Primary outcomes in two randomized controlled trials of treatments for cannabis use disorders, Drug and Alcohol Dependence, 118, 408, 10.1016/j.drugalcdep.2011.04.021 · DOI
- Comely, 2006, Assessment and treatment of cannabis abuse and dependence - a practitioner's perspective, Australian Journal of Psychology, 58, 125
- Croquette-Krokar, 2004, Cannabis abuse in adolescents. A comparison of clients attending two specific psychotherapeutic units using a common assessment instrument, European Psychiatry, 19, 160S
- Fohlmann, 2008, The CapOpus treatment model - a specialized 6-month treatment program for young outpatients with cannabis abuse and psychosis, Early Intervention in Psychiatry, 2, A121
- Fohlmann, 2010, CapOpus. Randomized clinical trial: specialized addiction treatment (MI & CBT) versus treatment as usual for young patients with cannabis abuse and psychosis, Early Intervention in Psychiatry, 4, 160
- Hjorthoj, 2008, Preliminary results of the CapOpus trial comparing specialized treatment with treatment as usual for cannabis misuse in people with comorbid psychosis and cannabis misuse, Early Intervention in Psychiatry, 2, A122
- Hjorthoj, 2012, CapOpus - intervention study for cannabis use disorder in psychosis, Early Intervention in Psychiatry, 6, 28
- Huesler, 2006, A binational (Switzerland, Germany) intervention program for cannabis abusers, Psychology and Health, 21, 68
- Liddle, 2002, A randomized controlled trial of intensive outpatient, family-based therapy vs. residential drug treatment for co-morbid adolescent substance abusers, Drug and Alcohol Dependence, 66, S1
- Metrik, 2010, Balanced-placebo design successfully adapted for use with marijuana, DATA: The Brown University Digest of Addiction Theory and Application, 29, 8
- Smeerdijk, 2009, Family motivation intervention in early onset psychosis and cannabis abuse: a randomized clinical trial, Schizophrenia Bulletin, 35, 371
- Swift, 2001, Adolescent cannabis check-up and intervention trial, Drug and Alcohol Dependence, 63, 156
- Werder, 2012, Addressing marijuana use as an early intervention in youth with serious mental illness, Early Intervention in Psychiatry, 6, 97
- Copeland, 2001, Clinical profile of participants in a brief intervention program for cannabis use disorder, Journal of Substance Abuse Treatment, 20, 45, 10.1016/S0740-5472(00)00148-3 · DOI
- European Monitoring Centre for Drugs and Drug Addiction, 2014, European Drug Report 2014: Trends and Developments
- European Monitoring Centre for Drugs and Drug Addiction, 2012, 2012 Annual Report on the State of the Drug Problem in Europe
- Miller, 1992, Motivational Enhancement Therapy Manual. NIAAA Project MATCH Monograph Series. Publication No. (ADM) 92-1894
- Substance Abuse and Mental Health Services Administration, 2002, Marijuana treatment admission increase: 1993-1999
- Substance Abuse and Mental Health Services Administration, 2013, The TEDS Report: Marijuana Admissions Aged 18 to 30: Early vs. Adult Initiation
- Substance Abuse and Mental Health Services Administration, 2014, Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. NSDUH Series H-48, HHS Publication No. (SMA) 14-4863
- World Health Organization, 1992, The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines
Cited by
Sorted by citations
Items 101–200 of 280
Kearney-Ramos, T. E., & Haney, M. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110290 · Cited by 12
The effect of cannabis policies on treatment outcomes for cannabis use among U.S. adults
Bourdon, J. L., Francis, M. W., Jia, L. S., Liang, C., Robinson, H., & Grucza, R. A. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108535 · Cited by 14
Borodovsky, J. T., Sofis, M. J., Sherman, B. J., Gray, K. M., & Budney, A. J. (2022) · Psychology of Addictive Behaviors · doi:10.1037/adb0000817 · Cited by 14
Cannabis and the Current State of Treatment for Cannabis Use Disorder
Williams, A. R., & Hill, K. P. (2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20180038 · Cited by 14
Hersi, M., Corace, K., Hamel, C., Esmaeilisaraji, L., Rice, D., Dryburgh, N., Skidmore, B., Garber, G., Porath, A., Willows, M., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0292745 · Cited by 13
“, in-treatment or treatment seeking) [20, 21].”
Distinct neural networks predict cocaine versus cannabis treatment outcomes
Lichenstein, S. D., Köhler, R., Ye, F., Potenza, M. N., Kiluk, B. D., & Yip, S. W. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02120-0 · Cited by 13
When and How to Treat Possible Cannabis Use Disorder
Lévesque, A., & Foll, B. L. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.02.009 · Cited by 13
Cannabis Use and Psychiatric Disorders: Implications for Mental Health and Addiction Treatment
Halah, M. P., Zochniak, M. P., Barr, M. S., & George, T. P. (2016) · Current Addiction Reports · doi:10.1007/s40429-016-0128-5 · Cited by 13
Rains, L. S., Steare, T., Mason, O. J., & Johnson, S. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-034735 · Cited by 13
Pharmacotherapies for cannabis use disorder
Spiga, F., Parkhouse, T., Tang, V. M., Savović, J., Foll, B. L., & Nielsen, S. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008940.pub4 · Cited by 12
Connor, J. P., Manthey, J., Hall, W., & Stjepanović, D. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01829-5 · Cited by 14
N-acetylcysteine for youth cannabis use disorder: randomized controlled trial main findings
Gray, K. M., Tomko, R. L., Baker, N. L., McClure, E. A., McRae‐Clark, A. L., & Squeglia, L. M. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02061-y · Cited by 12
Cénat, J. M., Kogan, C. S., Kebedom, P., Ukwu, G., Farahi, S. M. M. M., Darius, W. P., Bakombo, S. M., Dalexis, R. D., Ndengeyingoma, A., Noorishad, P., et al. (2022) · Addictive Behaviors · doi:10.1016/j.addbeh.2022.107567 · Cited by 12
Soyka, M., Preuss, U. W., & Hoch, E. (2017) · Der Nervenarzt · doi:10.1007/s00115-017-0281-7 · Cited by 12
Dual Disorders: Addiction and Other Mental Disorders. Integrating Mental Health
Szerman, N., Parro-Torres, C., Didia-Attas, J., & el‐Guebaly, N. (2018) · Springer eBooks · doi:10.1007/978-3-319-70554-5_7 · Cited by 12
Hodgins, D. C., & Stea, J. N. (2018) · Addiction Science & Clinical Practice · doi:10.1186/s13722-018-0118-0 · Cited by 11
Fond, G. B., Picot, A., Bourbon, A., Boucékine, M., Auquier, P., Lançon, C., & Boyer, L. (2020) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01131-0 · Cited by 11
Tatar, O., Abdel‐Baki, A., Tra, C., Mongeau‐Pérusse, V., Arruda, N., Kaur, N., Landry, V., Coronado‐Montoya, S., & Jutras‐Aswad, D. (2021) · JMIR Formative Research · doi:10.2196/26562 · Cited by 11
Clinical Approaches to Cannabis
Slawek, D. E., Curtis, S. A., Arnsten, J. H., & Cunningham, C. O. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.08.004 · Cited by 11
Bhardwaj, A. K., Mills, L., Doyle, M., Sahid, A., Montebello, M., Monds, L., Arunogiri, S., Haber, P., Lorenzetti, V., Lubman, D. I., et al. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05616-3 · Cited by 10
Feingold, D., Bitan, D. T., Ferri, M., & Hoch, E. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01781-4 · Cited by 12
Review of systemic and syndromic complications of cannabis use: A review
Shah, J., & Fermo, O. P. (2022) · Medicine · doi:10.1097/md.0000000000032111 · Cited by 10
Tomko, R. L., Wolf, B. J., McClure, E. A., Carpenter, M. J., Magruder, K. M., Squeglia, L. M., & Gray, K. M. (2023) · Addiction · doi:10.1111/add.16226 · Cited by 10
Cannabis Use Disorder: Recent Findings and Future Directions
Kimmel, H. L., & Lopez, M. F. (2018) · Current Addiction Reports · doi:10.1007/s40429-018-0223-x · Cited by 10
Marino, L. A., Jankowski, S. E., Kent, R., Birnbaum, M. L., Nossel, I. R., Alves-Bradford, J.-M. E., & Dixon, L. B. (2021) · Early Intervention in Psychiatry · doi:10.1111/eip.13176 · Cited by 10
Tatar, O., Abdel‐Baki, A., Dyachenko, A., Bakouni, H., Bahremand, A., Tibbo, P. G., Crockford, D. N., Roy, M., Copeland, J., Fischer, B., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115276 · Cited by 15
Self-citationPrevalence and Treatment of Substance Misuse in Older Adults: Beyond Early Adulthood
Hu, J., Kulkarni, N., Maliha, P., & Grossberg, G. T. (2024) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s375653 · Cited by 9
Factor analysis of a short form of the Protective Behavioral Strategies for Marijuana scale
Mian, M. N., Altman, B. R., Luba, R. R., Ueno, L. F., Dalal, D. K., & Earleywine, M. (2021) · Addictive Behaviors · doi:10.1016/j.addbeh.2021.106852 · Cited by 9
Psychotherapeutic interventions for cannabis use disorder. What do we know and what should we do?
Pouliquen, M. D., & Auriacombe, M. (2021) · L Encéphale · doi:10.1016/j.encep.2021.05.009 · Cited by 10
Mills, L., Dunlop, A. J., Montebello, M. E., Copeland, J., Bruno, R., Jefferies, M., McGregor, I. S., & Lintzeris, N. (2022) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-022-00493-z · Cited by 9
Self-citationLee, J. D., Schatz, D., & Hochman, J. S. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.010 · Cited by 9
Mauro, P. M., Gutkind, S., Askari, M. S., Hasin, D. S., Samples, H., Mauro, C., Annunziato, E. M., Boustead, A. E., & Martins, S. S. (2024) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2024.111113 · Cited by 10
Cannabis use disorder: an overview of treatment approaches in Europe
Hoch, E., Murawski, M., Ferri, M., & Feingold, D. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-025-01964-7 · Cited by 10
A Holistic Review of Cannabis and Its Potential Risks and Benefits in Mental Health
Borrego-Ruiz, A., & Borrego, J. J. (2025) · Psychiatry International · doi:10.3390/psychiatryint6030092 · Cited by 13
Macatee, R. J., Preston, T. J., Afshar, K., Schmidt, N. B., & Cougle, J. R. (2022) · Psychology of Addictive Behaviors · doi:10.1037/adb0000815 · Cited by 8
Applications of technology in the assessment and treatment of cannabis use disorder
Brezing, C., & LEVIN, F. R. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1035345 · Cited by 8
Precipitated Δ9-THC withdrawal reduces motivation for sucrose reinforcement in mice
Eckard, M. L., Trexler, K. R., Kotson, B. T., Anderson, K. G., & Kinsey, S. G. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172966 · Cited by 8
Towobola, A., Towobola, B., Nair, B., & Makwana, A. P. (2021) · BJPsych Bulletin · doi:10.1192/bjb.2021.102 · Cited by 9
Evers, Y. J., Camp, K. O. D., Lenaers, M., Dukers–Muijrers, N. H. T. M., & Hoebe, C. J. P. A. (2022) · Sexually Transmitted Infections · doi:10.1136/sextrans-2021-055355 · Cited by 8
Moss, A. C., Silva, D. D., Cox, S., Notley, C. J., & Nanda, M. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229905 · Cited by 7
Group versus individual treatment for substance use disorders: a study protocol for the COMDAT trial
Karsberg, S., Pedersen, M. U., Hesse, M., Thylstrup, B., & Pedersen, M. M. (2021) · BMC Public Health · doi:10.1186/s12889-021-10271-4 · Cited by 7
Is Cannabis Use Treatment Also Indicated for Patients with Low to Moderate Polysubstance Use
Neumann, M., Bühringer, G., Höfler, M., Wïttchen, H., & Hoch, E. (2018) · European Addiction Research · doi:10.1159/000488345 · Cited by 7
Macatee, R. J., Cannon, M. J., Schermitzler, B. S., Preston, T. J., & Afshar, K. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.04.016 · Cited by 6
Kritikos, A. F., Taylor, B. G., Lamuda, P. A., Pollack, H. A., & Schneider, J. A. (2025) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2025.112680 · Cited by 6
Graves, B. D., Mowbray, O. P., Aletraris, L., & O’Shields, J. (2025) · Substance Use & Misuse · doi:10.1080/10826084.2025.2505773 · Cited by 6
Getty, C., Weaver, T. D., & Metrebian, N. (2022) · Drug and Alcohol Review · doi:10.1111/dar.13555 · Cited by 6
Roméo, B., Kervadec, E., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Verroust, V., Piolino, P., & Benyamina, A. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2375720 · Cited by 6
Montebello, M. E., Jefferies, M., Mills, L., Bruno, R., Copeland, J., McGregor, I. S., Rivas, C., Jackson, M. A., Silsbury, C., Dunlop, A. J., et al. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109388 · Cited by 6
Self-citationMauro, P. M., Gutkind, S., Rivera‐Aguirre, A., Gary, D. S., Cerdá, M., Santos, É. C., Castillo‐Carniglia, Á., & Martins, S. S. (2022) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2022.103810 · Cited by 6
Adolescent cannabis use disorders
Leung, J., Hall, W., & Degenhardt, L. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818626-8.00004-9 · Cited by 8
Cannabis Use Among Patients With Psychotic Disorders
Hirschtritt, M. E., Young‐Wolff, K. C., Mathalon, D. H., & Satre, D. D. (2021) · The Permanente Journal · doi:10.7812/tpp/20.179 · Cited by 6
Commentary: Expressed emotion as a mechanistic target in psychosis early intervention
Kline, E. R. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.05.011 · Cited by 6
Barkus, A., Baltrūnienė, V., Barkienė, L., Baušienė, J., Baltrūnas, T., Brazys, M., Rauduvytė, K., Kazlauskaitė, P., & Baušys, A. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70165 · Cited by 7
Trends in cannabis use disorder and treatment by race and ethnicity, 2002–2019
Roura, M. T., Vora, A., Eschliman, E. L., & Mauro, P. M. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1689719 · Cited by 7
Cannabis Use Disorder in the Era of Legalization: Implications for Addiction Treatment Systems
Bahji, A. (2026) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s581271 · Cited by 5
Cannabis Use Disorder Treatment Preferences: A Pilot Survey in Current Users of Cannabis
Lile, J. A., Turner, B. W., Cox, D. H., Bonn‐Miller, M. O., Katz, N. R., Shellenberg, T., Stoops, W. W., & Strickland, J. C. (2022) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001059 · Cited by 5
Vederhus, J., Rørendal, M., Skårdal, M., Næss, M. O., Clausen, T., & Kristensen, Ø. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269988 · Cited by 5
Xie, Z., Stallings‐Smith, S., Stetten, N. E., Hamadi, H. Y., & Marlow, N. M. (2023) · American Journal on Addictions · doi:10.1111/ajad.13485 · Cited by 5
The Treatment of Cannabis Use Disorder
Danovitch, I., & Gorelick, D. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54856-4.00007-9 · Cited by 5
Overview of Current State-of-the-Art Treatments for Cannabis Use Disorders, and Future Directions
Copeland, J., Pokorski, I., & Gibson, L. (2017) · Current Addiction Reports · doi:10.1007/s40429-017-0151-1 · Cited by 5
Self-citationLoscertales, H. R., Wentzky, V., Dürsteler, K. M., Strasser, J., Hersberger, K. E., & Arnet, I. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317690502 · Cited by 5
Posverdad del consumo de cannabis: de regreso a la medicina basada en la evidencia
López‐Pelayo, H., de Montagut, L. M., Casajuana, C., & Balcells-Oliveró, M. (2018) · Adicciones · doi:10.20882/adicciones.1095 · Cited by 5
Davis, A. K., Arterberry, B. J., Xin, Y., Hubbard, S. M., Schwarting, C. M., & Bonar, E. E. (2023) · Cannabis · doi:10.26828/cannabis/2023/000180 · Cited by 4
3-Year Follow-up of Lower Risk Cannabis Use Patterns: Evidence from a Longitudinal Survey
Chen, T., Hassan, A. N., & Foll, B. L. (2021) · The Canadian Journal of Psychiatry · doi:10.1177/0706743721996118 · Cited by 4
Promoting self-change in cannabis use disorder: Findings from a randomized trial
Schluter, M. G., Hodgins, D. C., Stea, J. N., & Kilborn, M. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1015443 · Cited by 5
Randomized controlled trial of zolpidem as a pharmacotherapy for cannabis use disorder
Lee, D. C., Schlienz, N. J., Herrmann, E. S., Martin, E. L., Leoutsakos, J., Budney, A. J., Smith, M. T., Tompkins, D. A., Hampson, A. J., & Vandrey, R. G. (2023) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2023.209180 · Cited by 4
Trick, L., Butler, K., Bourgault, Z., Vandervoort, J., & Foll, B. L. (2023) · Substance Abuse Research and Treatment · doi:10.1177/11782218231205840 · Cited by 4
Neuromodulation for Cannabis Use: A Scoping Review
Ngoy, A., Tang, V. M., Xiao, K., Blumberger, D. M., George, T. P., Gowin, J. L., Foll, B. L., & Sloan, M. E. (2024) · Brain Sciences · doi:10.3390/brainsci14040356 · Cited by 4
Mian, M. N., Annam, J., Altschuler, A., Does, M. B., Sterling, S., Satre, D. D., Campbell, C. I., Asyyed, A. H., Silver, L. D., Cunningham, S. F., et al. (2024) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2024.209559 · Cited by 5
Cannabis, Cannabinoide und Cannabiskonsumstörungen
Hoch, E., & Preuss, U. W. (2019) · PSYCH up2date · doi:10.1055/a-0847-9296 · Cited by 4
Woehler, E. S., & Ray, D. C. (2022) · The Journal of Humanistic Counseling · doi:10.1002/johc.12185 · Cited by 5
Review of cannabis use among Aboriginal and Torres Strait Islander people
Butt, J., Wilson, M., Jones, J., & Lenton, S. R. (2022) · Journal of the Australian Indigenous HealthInfoNet · doi:10.14221/aihjournal.v3n3.1 · Cited by 4
Wolfe, D. M., Hutton, B., Corace, K. M., Chaiyakunapruk, N., Ngorsuraches, S., Nochaiwong, S., Presseau, J., Grant, A., Suschinsky, K. D., Skidmore, B., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-064578 · Cited by 4
A randomized controlled trial of brief intervention for patients with cannabis use disorder
Shekhawat, A. S., Mathur, R., Sarkar, S., Kaloiya, G. S., & Balhara, Y. P. S. (2023) · Journal of Neurosciences in Rural Practice · doi:10.25259/jnrp_79_2023 · Cited by 4
The Need to Focus Research on Adolescent Cannabis Use Interventions
Adelman, W. P. (2020) · PEDIATRICS · doi:10.1542/peds.2020-012336 · Cited by 4
Ghelani, A. (2020) · The Journal of Sociology & Social Welfare · doi:10.15453/0191-5096.4367 · Cited by 4
Cannabidiol for cannabis use disorder: too high hopes?
Hjorthøj, C. R., Posselt, C. M., & Baandrup, L. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30378-3 · Cited by 4
Beyond abstinence: Redefining success in cannabis use disorder treatment
Atkin, T., LEVIN, F. R., MARIANI, J., & Brezing, C. (2026) · Addiction · doi:10.1111/add.70517 · Cited by 3
Maddern, X. J., Walker, L. C., Campbell, E. J., Arunogiri, S., Haber, P., Morley, K. C., Manning, V., Millan, E. Z., McNally, G. P., Lubman, D. I., et al. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104899 · Cited by 4
Coronado‐Montoya, S., Abdel‐Baki, A., Crockford, D. N., Côté, J., Dubreucq, S., Dyachenko, A., Fischer, B., Lecomte, T., L’Heureux, S., Ouellet‐Plamondon, C., et al. (2024) · The Canadian Journal of Psychiatry · doi:10.1177/07067437241242395 · Cited by 3
Cannabis Use Disorder Among People With and Without HIV
Haley, D. F., So‐Armah, K., Justice, A. C., Kidwai‐Khan, F., Xuan, Z., Adams, R. S., Fox, M. P., Edelman, E. J., Wrona, A., Silverberg, M. J., et al. (2025) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000001505 · Cited by 3
Emerging pharmacological strategies for the treatment of cannabis use disorder
Bahji, A. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2558999 · Cited by 4
Boska, G. D. A., de Oliveira, M. A. F., & Seabra, P. (2021) · Health & Social Care in the Community · doi:10.1111/hsc.13539 · Cited by 3
Cannabis, Cannabinoide und Cannabiskonsumstörungen
Hoch, E., & Preuss, U. W. (2019) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-1008-7427 · Cited by 3
Kwon, C., Lee, B., Chung, S.-Y., & Kim, J. W. (2020) · EXPLORE · doi:10.1016/j.explore.2020.05.016 · Cited by 4
Mindfulness-Based Practices for the Treatment of Cannabis Use Disorder
Shurtleff, D. (2018) · Springer eBooks · doi:10.1007/978-3-319-90365-1_24 · Cited by 3
Narasimha, V. L., Shukla, L., Shyam, R. S., Kandasamy, A., & Benegal, V. (2019) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_16_19 · Cited by 3
Mostardinha, A. R., & Pereira, A. (2020) · Psychology Community & Health · doi:10.5964/pch.v8i1.304 · Cited by 3
Fischer, B., Daldegan‐Bueno, D., Bell, R., Boden, J. M., Bullen, C., Farrell, M., Hall, W., & Newcombe, D. A. L. (2020) · Public Health in Practice · doi:10.1016/j.puhip.2020.100046 · Cited by 3
Evaluación de activación conductual en universitarios que consumen mariguana: estudio piloto
Torres, E. S. B., Morales, S. E. C., & Mandujano, J. L. (2021) · Revista Internacional de Investigación en Adicciones · doi:10.28931/riiad.2021.2.02 · Cited by 3
Hämmig, R., Preuss, U. W., & Soyka, M. (2018) · Elsevier eBooks · doi:10.1016/b978-3-437-23021-9.00009-6 · Cited by 3
Kuyokwa, J., Banda, D. M., Chiziwa, S., & Semphere, N. (2024) · Journal of Humanities and Social Sciences Studies · doi:10.32996/jhsss.2024.6.3.5 · Cited by 2
Lapham, G. T., Bobb, J. F., Luce, C., Oliver, M. M., Hamilton, L., Hyun, N., Hallgren, K. A., & Matson, T. E. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-09061-6 · Cited by 2
Tustin, R. D. (2025) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph22040612 · Cited by 3
A Scoping Review of Cultural Variables in Contingency Management for Substance Use Disorder
Donohue, H. E., Foster, B. A., & Dallery, J. (2025) · Perspectives on Behavior Science · doi:10.1007/s40614-025-00480-2 · Cited by 3
Middleton-Curran, L., Rains, L. S., Taylor, J., Morant, N. J., & Johnson, S. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281368 · Cited by 2
Rethinking Substance Use as Social History: Charting a Way Forward
Bozinoff, N., Kleinman, R. A., Sloan, M. E., Kennedy, M. C., Nolan, S., Selby, P. L., Kalocsai, C., & Wood, E. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-08642-9 · Cited by 2
Stampf, A., Schwarzkopf, L., Batalla, A., Feingold, D., Fischer, B., Hoch, E., Advisory Board of the German Addiction Care Statistical Service, Bachmeier, R., Mäder-Linke, C., Egartner, E., et al. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01832-w · Cited by 2
Chauhan, D., Ghosh, A., Naik, S. S., Rana, D. K., & Singh, S. M. (2024) · Journal of Ect · doi:10.1097/yct.0000000000001087 · Cited by 2
Reaching nontreatment-seeking cannabis users: Testing an extended marijuana check-up intervention
Stephens, R. S., Walker, R., Fearer, S. A., & Roffman, R. A. (2020) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2020.108269 · Cited by 2
Metadata
- Authors
- Gates, P. J., Sabioni, P., Copeland, J., Le Foll, B., & Gowing, L.
- Affiliations
- UNSW Sydney (AU)
- Centre for Addiction and Mental Health (CA)
- University of Toronto (CA)
- Centre for Addiction and Mental Health; University of Toronto; Translational Addiction Research Laboratory; 33 Russell Street Toronto ON Canada
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2016-05-05
- Issue
- 5
- Pages
- CD005336-CD005336
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- PMC
- PMC4914383
- OpenAlex
- W2414702405
- Cited by
- 282
- References
- 182
- Citations by year
- 2026: 13 · 2025: 24 · 2024: 33 · 2023: 28 · 2022: 35 · 2021: 31 · 2020: 34 · 2019: 36 · 2018: 27 · 2017: 18 · 2016: 2
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cochrane Database of Systematic Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Funders
- National Institute on Drug Abuse (R21DA031906)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Keywords
- cannabis use disorder, psychosocial interventions, treatment efficacy, outpatient care, community-based treatment, treatment completion, relapse, medication adherence, substance use disorders
- MeSH terms
- Ambulatory Care, Marijuana Abuse, Humans, Cognitive Behavioral Therapy, Randomized Controlled Trials as Topic, Motivational Interviewing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
